Introduction {#Sec1}
============

Metabolic Syndrome (MetS) is characterized by a cluster of risk factors for insulin resistance (IR) type 2 diabetes mellitus (T2DM) and cardiovascular disease, including obesity, hypertension, hyperglycemia, and dyslipidemia^[@CR1]^. Individuals with MetS have a 24-fold increased risk for the development of T2DM^[@CR2]^ and are known to be more susceptible to the development of cardiac vascular diseases^[@CR3]^ and cancers^[@CR4],[@CR5]^. Due to the increasing prevalence of MetS, especially in developing countries^[@CR6]--[@CR8]^, it is urgent to discover new strategies for the assessment and treatment of MetS. However, while insulin resistance (IR) is considered to be a major factor in MetS, the exact pathophysiology is unknown although complex genetic, metabolic and environmental factors do play a role^[@CR9]^. Therefore, it is important to study all factors related to MetS in depth.

Bone morphogenetic protein-9 (BMP-9), a member of transforming growth factor (TGF-β) superfamily, was initially found in hepatocytes and intrahepatic biliary epithelial cells^[@CR10]^. Subsequently, an additional pattern of distribution was reported^[@CR11],[@CR12]^. BMP-9 was originally identified as relating to chondrogenic and osteogenic factors^[@CR13]^. Recently, however, some animal studies have demonstrated that BMP-9 has multiple functions including angiogenesis, promoting the differentiation of cholinergic neurons in the central nervous system (CNS) and regulating hepatic growth^[@CR14]--[@CR16]^. BMP-9 has also been shown to regulate the key enzymes of fatty acid synthesis in the liver, promote insulin release from the pancreas, suppress hepatic glucose production (HGP) and increase brown adipogenesis in adipose tissue^[@CR17],[@CR18]^. In our recently published study, we showed that circulating BMP-9 levels are significantly lower in newly diagnosed patients with T2DM (nT2DM) than in healthy subjects and BMP-9 levels are associated with HbA~1~c~,~ fasting blood glucose (FBG), 2-h plasma glucose after glucose overload (2-h OGTT, the area under the curve for glucose (AUC~glucose~) and homeostasis model assessment of insulin resistance (HOMA-IR)^[@CR19]^. However, to date, there have been no studies that accurately assess the clinical relevance of the relationship between BMP-9 and MetS.

In the current study, our aim is to assess the association between circulating BMP-9 levels and MetS as well as the number of components and plasma BMP-9 levels in middle-aged and older Chinese populations.

Results {#Sec2}
=======

Anthropometric and metabolic parameters in study subjects {#Sec3}
---------------------------------------------------------

A total of 362 participants were enrolled for the analysis. Baseline characteristics of the study subjects are shown in Table [1](#Tab1){ref-type="table"}. No significant differences were observed in age and sex between control subjects and MetS patients. Compared with controls, Mets subjects had higher BMI, FAT (%), Waist hip ratio (WHR), Systolic blood pressure (SBP), Diastolic blood pressure (DBP), triglyceride (TG), cholesterol (TC), Low-density lipoprotein cholesterol (LDL-C), free fatty acid (FFA), HBA1c(%), FBG, 2-h post-glucose load blood glucose (2h-PBG), FIns, HOMA-IR and lower High-density lipoprotein cholesterol (HDL-C) (*P* \< 0.01 or *P* \< 0.05). After control for age and sex, the differences still existed.Table 1Main clinical features in MetS and control subjects.VariableControls (n = 147)MetS (n = 215)PAge (yr)53.8 ± 9.254.6 ± 8.20.124Sex (femal %)59.9% (88, 59)54.4% (117, 98)0.332BMI (kg/m^2^)22.9 ± 3.025.4 ± 2.6\<0.001FAT (%)26.3 ± 5.931.3 ± 7.0\<0.001WHR0.87 ± 0.080.93 ± 0.06\<0.001SBP (mmHg)116.8 ± 15.0131.8 ± 18.6\<0.001DBP (mmHg)73.5 ± 9.682.6 ± 12.1\<0.001TC (mmol/L)4.59 ± 1.034.90 ± 1.350.021TG (mmol/L)1.15 (0.80--1.50)2.00 (1.40--2.70)\<0.001HDL-C (mmol/L)1.40 ± 0.601.10 ± 0.25\<0.001LDL-C (mmol/L)2.67 ± 0.762.90 ± 0.980.015FFA (µmol/L)0.51 (0.38--0.65)0.64 (0.44--0.90)\<0.001HBA1c (%)5.6 ± 0.47.1 ± 1.9\<0.001FBG (mmol/L)5.2 ± 0.67.8 ± 4.0\<0.0012h-BG (mmol/L)6.3 ± 1.213.2 ± 8.2\<0.001FIns (mU/L)8.6 (5.6--13.0)(143)15.8 (9.5--22.7)(174)\<0.001HOMA-IR1.97 (1.30--3.02)(143)5.04 (3.66--6.75)(174)\<0.001BMI, Body mass index; FAT (%), the percentage of fat *in vivo*; WHR, Waist hip ratio; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; TG, Triglyceride; TC, Total cholesterol; HDL-C, High- density lipoprotein cholesterol; LDL-C, Low-density lipoprotein cholesterol; FFA, free fatty acid; HbA1c, Glycosylated hemoglobin; FBG, Fasting blood glucose; 2h-BG, 2 h post-glucose load blood glucose; FIns, Fasting plasma insulin; HOMA-IR, HOMA-insulin resistance index. Values are means ± SD or median (interquartile Range).

Subgroup analysis {#Sec4}
-----------------

In the analysis of subgroup, fasting BMP-9 levels were similar in both male and female (Table [2](#Tab2){ref-type="table"}), suggesting that this hormone does not exhibit distinct sexual dimorphism. Subjects with central obesity, defined by the MetS (NCEP ATPIII) Asian criteria, had significantly lower circulating BMP-9 levels than lean individuals in the study population (*P* \< 0.05, Table [2](#Tab2){ref-type="table"}). In addition, individuals with dyslipidemia or hypertension had significantly lower plasma BMP-9 levels than those without (all *P* \< 0.01, Table [2](#Tab2){ref-type="table"}). Importantly, fasting circulating levels of BMP-9 were significantly lower in MetS subjects compared with healthy controls \[44.31(29.77, 66.39) *vs*. (78.39 (47.78, 140.29) ng/L, *P* \< 0.01; Table [2](#Tab2){ref-type="table"}, Fig. [1A](#Fig1){ref-type="fig"}\]. To further explore the relationship between BMP-9 and the MetS, we stratified the mean levels of circulating BMP-9 by the number of components of the MetS. We found that circulating concentrations of BMP-9 significantly decreased with more than 3 components of MetS (*P* for trend \< 0.01, Fig. [1B](#Fig1){ref-type="fig"}). Subjects with more components of MetS had decreased BMP-9 levels (BMP-9 levels were log transformed, mean ± SD) of 4.41 ± 0.81; 4.36 ± 0.94; 3.87 ± 0.76; 3.85 ± 0.73; 3.70 ± 4.36, respectively.Table 2Plasma BMP-9 levels according to gender and various clinical phenotypes.Clinical phenotypenBMP-9 (ng/L)*P*-valueFemale20554.75(34.76,88.38)Male15751.38(31.20,97.13)0.789Central obesity23750.93(32.01,83.48)Non-central obesity12561.58(38.71,102.31)\<0.05Dyslipidemia27049.73(32.11,84.29)Normal lipid9275.72(45.93,109.00)\<0.001IR14349.17(32.27,82.57)Non-IR17468.48(43.94,114.51)\<0.001Hypertension19349.72(31.20,81.25)Normal BP16959.75(35.19,110.75)\<0.001MetS21544.31(29.77,66.39)Non-MetS14778.39(47.78,140.29)\<0.001IR, insulin resistance; BP, blood pressure. Data are expressed as median (interquartile range). Figure 1(**A**) Circulating BMP-9 levels in control and MetS individuals. (**B**) Circulating BMP-9 levels in relation to the number of MetS components. The values of BMP-9 are log-transformed. (**C**) Prevalence of elevated MetS in different quartiles f BMP-9: tertile 1, ≤ 39.49 ng/L; tertile 2, 39.49--75.93 ng/L; tertile 3, \> 75.93 ng/L (\**P* \< 0.01 *vs*. controls or tertile 1).

Circulating BMP-9 level and its association with anthropometric and biochemical parameters in study subjects {#Sec5}
------------------------------------------------------------------------------------------------------------

Next, we further analyzed the correlations of plasma BMP-9 levels with anthropometric and metabolic parameters by using spearman correlations. We found that circulating BMP-9 levels negatively correlated with marker of adiposity (WHR), IR marker (HOMA-IR), parameters of glucose metabolism (FBG, 2h-PBG and HbA1c) and parameters of blood fat (TG), while positively correlated with HDL-C and FFA (*P \< *0.05 or *P* \< 0.01, Table [3](#Tab3){ref-type="table"}). All these correlations remained statistically significant after further adjustment for age and sex in partial correlations. There were no correlations between circulating BMP-9 with fasting and 2 h post-glucose load insulin levels. Multiple stepwise regression analysis showed that FFA, T2DM and HOMA-IR were independent related factors with plasma BMP-9 levels (Table [4](#Tab4){ref-type="table"}). The multiple regression equation was: *Y* ~BMP-9~ = 4.469 + 0.160 *X* ~FFA~ − 0.294*X* ~T2DM~ − 0.296*X* ~HOMA-IR~ (*P* \< 0.01, R^2^ = 0.10).Table 3The correlation analysis of plasma BMP-9 levels with other variables in study subjects.Variable*rP*Age (yr)−0.0820.125BMI (kg/m^2^)−0.0470.378WHR−0.145\<0.001FAT (%)−0.0990.062SBP (mmHg)−0.0170.745DBP (mmHg)−0.0240.649FBG (mmol/L)−0.154\<0.0012h-OGTT (mmol/L)−0.232\<0.001HbA1c (%)−0.161\<0.001TG (mmol/L)^a^−0.1160.031TC (mmol/L)0.0160.767HDL-C (mmol/L)^a^0.188\<0.001LDL-C (mmol/L)0.0340.538FFA (µmol/L)0.189\<0.001HOMA-IR^a^−0.150\<0.001FIns (mU/L)−0.0240.666In pearson correlation analysis, values included for analysis were age, BMI, WHR, BP, FBG, insulin, HOMA-IR, FFA, total cholesterol, HDL-C, LDL-C, triglyceride. ^a^log-transformed values. Table 4Multiple stepwise regression showing variables with significant independent associations with plasma BMP-9.Coefficient β95%CI*P*Age−0.0130.826Sex0.1430.886FFA0.1600.029--0.291\<0.01Central obesity−0.0200.853Dyslipidemia−0.0490.842T2DM−0.294−0.497--(−0.090)\<0.01HOMA-IR−0.296−0.496--(−0.105)\<0.01BMP-9 was log-transformed before analysis.

The predictive value of circulating BMP-9 in detecting MetS and dyslipidemia {#Sec6}
----------------------------------------------------------------------------

Binary logistic regression showed that plasma BMP-9 concentrations were significantly associated with MetS even after controlling for anthropometric variables and lipid profile (Table [5](#Tab5){ref-type="table"}). In addition, we divided BMP-9 into three tertiles according to the BMP-9 concentration of the study population (tertile 1, ≤39.49 ng/L; tertile 2, 39.49--75.93 ng/L; tertile 3, \>75.93 ng/L) and odds of developing MetS were calculated using logistic regression analysis. When BMP-9 levels were in the tertile 2 and tertile 3, the odds ratios of developing MetS were 0.461 (95% CI 0.259; 0.819) and 0.145 (95% CI 0.081; 0.258), respectively (*vs*. tertile 1, both *P* \< 0.01; Fig. [1C](#Fig1){ref-type="fig"}). When concentrations were analyzed by row mean score difference and the Cochran-Armitage trend test (Table [6](#Tab6){ref-type="table"}), decreasing BMP9 levels showed a significant linear trend and were independently associated with MetS. Finally, we performed the ROC curve of BMP-9 circulating levels in predicting MetS and dyslipidemia (Fig. [2](#Fig2){ref-type="fig"}). The area under the ROC curves was 0.70 (*P* \< 0.001) with a sensitivity of 69.4%, specificity of 68.4% for MetS (Figs. [2A](#Fig2){ref-type="fig"}) and 0.61 (P \< 0.01) with a sensitivity of 68.5%, specificity of 58.5% for dyslipidemia (Fig. [2B](#Fig2){ref-type="fig"}). The best cutoff values for circulating BMP-9 to predict MetS and dyslipidemia were 56.6 and 54.9 ng/L.Table 5Association of circulating BMP-9 levels with MetS in fully adjusted models.Model adjustMetSOR95%CI*P*Age, Sex0.5290.393--0.711\<0.001Age, Sex, BMI, WHR, FAT (%)0.4970.3543--0.699\<0.001Age, Sex, BMI, WHR, FAT (%), SBP, DBP0.4320.295--0.632\<0.001Age, Sex, BP, BMI, WHR, FAT(%), lipid profile0.3610.224--0.582\<0.001Results of binary logistic regression analysis are presented as the odds ratio (OR) of being in MetS status decrease in circulating. BMI, body mass index; WHR, waist-to-hip; FAT (%), the percentage of fat *in vivo*; SBP, systolic blood pressure; DBP, diastolic blood pressure; lipid profile, including total cholesterol, FFA, triglyceride, LDL- and HDL-cholesterol. Table 6Row mean scores and Cochran--Armitage trend test of the impact of plasma BMP-9 level on MetSModel adjustedMetSχ^2^*P*-valueRow Mean Scores Test12.2353\<0.001Cochran-Armitage Trend Test12.1915\<0.001The circulating BMP-9 levels of all subjects were cut-off and adjusted for age, sex, BMI, WHR, SBP, DBP, TC, TG, LDL-C and HDL-C. Figure 2ROC curve analysis was performed for the prediction of MetS **(A)** and dyslipidemia **(B)**.

Discussion {#Sec7}
==========

The major findings of the present study are 1) circulating BMP-9 levels are lower in subjects with MetS compared with healthy controls; 2) circulating concentrations of BMP-9 significantly decreased with more than 3 components of MetS; 3) plasma BMP-9 concentrations are significantly associated with MetS even after controlling for anthropometric variables, lipid profiles and hormone levels.

This study is the first report to analyze circulating BMP-9 levels with ELISA method in MetS subjects. Here, we showed that circulating BMP-9 levels in MetS are significantly decreased compared with the healthy controls, which is similar to a recent study of T2DM patients^[@CR19]^. In a subgroup analyses, we found that central obesity, dyslipidemia, hypertension and IR subjects also had lower circulating BMP-9 levels compared with controls. These findings further suggest that plasma BMP-9 might be relative to adiposity and obesity-related metabolic diseases, such as MetS.

BMP-9 has been shown to be a regulator of glucose and lipid metabolism^[@CR20]^. *In vitro*, BMP-9 inhibited the expression of phosphoenolpyruvate carboxykinase (PEPCK), increased fatty acid synthase (FAS) and activated the serine/threonine kinase AKT. In normal and diabetic mice, BMP-9 was shown to decrease glycemia^[@CR17]^. Furthermore, treatment with an anti-BMP-9 antibody in fasting rats induced glucose intolerance and IR^[@CR20]^. These data suggest a beneficial effect of BMP-9 on glucose and lipid metabolism and IR. Therefore, the reduction of circulating BMP-9 in subjects with MetS might be due to the increasing consumption in human body to counteract the metabolic stress imposed by MetS, including hyperinsulinemia, hyperglycemia and dyslipidemia. In addition, the decreased levels of BMP-9 may also be a result of both decreased formation and increased degradation in an IR state. However, the cross-sectional nature of the current study does not permit us to infer the causal relationship between BMP-9 and MetS. Therefore, a follow up study will be necessary.

Dyslipidemia and hyperglycemia have been shown to be two important components of MetS and have been added to the MetS definition. This is because it has been suggested that the disease progression in MetS subjects towards T2DM and cardiovascular diseases (CVD) is accompanied by increased metabolic abnormalities. Our data demonstrates that circulating BMP-9 levels in MetS patients are significantly correlated with FBG, 2h-PBG, HbA1c, FFA, HDL and TG, even after adjustment for age and sex. These results also suggest that prolonged hyperglycemia and hyperlipidemia in MetS patients are associated with decreased circulating BMP-9 levels. The positive correlation of BMP9 levels with HDL and negative correlation with HOMA-IR are concordant with the relationship between nonalcoholic fatty liver disease (NAFLD) and those same parameters^[@CR21]^. Therefore, we speculate that it is possible that low levels of BMP-9 predict NAFLD. Our multiple stepwise regression analysis has identified the FFA, T2DM and HOMA-IR, as significant independent contributors to circulating BMP-9 levels. This clinical evidence suggests that BMP-9 may play a regulatory role in glucose and lipid metabolism in humans, in keeping with the findings of an animal study that suggested a role of BMP-9 in the regulation of glucose and lipid metabolism^[@CR18]^. Taken together, these findings raise the possibility that BMP-9 acts as a mediator that links glucose and lipid metabolism, IR and MetS. Although it would be premature to conclude a causal effect of BMP-9 on these parameters, it would be of interest to explore whether interventions that specifically raise circulating BMP-9 levels would ameliorate metabolic disorder in MetS subjects.

MetS is a collection of abnormalities that increases the occurrence of CVD and T2DM. To investigate how BMP-9 is associated with CVD and T2DM risk, we compared the relationship between circulating BMP-9 levels and MetS components. We found that circulating concentrations of BMP-9 decreased progressively with continued increases in the number of MetS components. In particular, circulating BMP-9 levels positively correlated with LDL-C, an important risk factor for CVD. This suggests that low BMP-9 levels in MetS subjects may increase cardiovascular risk. In our ROC curve analysis, the results show that circulating BMP-9 may predict both MetS and dyslipidemia in our study population. However, the range of AUC (0.6--0.7) was considered to be of mild-to-moderate significance. Some possible explanation for this relatively weak result, include the sample size and a non-normal distribution of BMP-9 levels in study population. In addition, it is also possible that circulating BMP-9 may not be a good marker for predicting MetS. Therefore, further extensive studies are necessary.

Our study has several limitations. First, this cross-sectional study could not directly determine a causal relationship between BMP-9 and MetS. However, the crossover design minimizes inter-individual differences and ensures that the observed effects of BMP-9 are not attributable to differences in the study population; Second, the sample size was relatively small. However, it provided more than an 80% power to detect significant associations at the *r* \> 0.20 and the conventional *P* = 0.05 level; Third, this study is confined to specific age groups and a single race. The homogeny of our population sample decreases the generalizability of our results and decreases the applicability of the associations observed here between BMP-9 and MetS across populations. Therefore, future studies with larger sample sizes examining BMP-9 in various conditions and populations will be needed.

In summary, the results of the current study demonstrate that circulating levels of BMP-9 are decreased in subjects with MetS and associated with measures of IR (HOMA-IR), marker of adiposity (WHR), parameters of glucose metabolism (FBG, 2h-PBG and HbA1c) and parameters of blood fat (TG, HDL and FFA), and the presence of MetS. The strong negative associations of circulating BMP-9 with key components of MetS suggest that BMP-9 may be a potential prediction for risk assessment for cardiovascular disease in obese subjects.

Materials and Methods {#Sec8}
=====================

Subjects {#Sec9}
--------

This cross-sectional study was conducted from May 2015 to December 2016. A total of 362 subjects with newly diagnosed MetS patients (nMetS group, n = 215) and healthy controls (NGT group, n = 147) were recruited from the outpatients attending the Internal Medicine Department, community or schools through advertisement, and routine medical check-up. All individuals were screened for MetS. We used the United States National Cholesterol Education Program (NCEP) Expert Panel Adult Treatment Panel (ATP) III criteria as the recruitment criteria^[@CR22],[@CR23]^. Individuals meet 3 or more of the following conditions will be diagnosed as MetS: 1) central obesity (waist circumference; WC ≥ 90 or 80 cm for Asian male and female, respectively); 2) triglycerides (TG) ≥ 1.7 mmol/L; 3) low level of high-density lipoprotein-cholesterol (HDL-C; ≤40 mg/dL for male and ≤50 mg/dL for female); 4) blood pressure (BP) ≥130/85 mmHg or receiving antihypertensive medication; 5) fasting blood glucose (FBG) ≥5.6 mmol/L or known history of T2DM. Individuals with symptomatic heart failure, liver cirrhosis, hepatic and renal failure, long-term steroid use, cancer, active infection, or other medical problems that would confound the results of this investigation were excluded. All control subjects were selected by FBG \< 5.6 mmol/L and 2-h OGTT glucose \< 7.8 mmol/L, no family history of T2DM, no any other major illnesses, and no medication that could have affected laboratory test results. Normal subjects were in good health and had normal kidney and liver function. This study was conducted in accordance with the Declaration of Helsinki, and was approved by the human research ethics committee of Chongqing Medical University, and informed consent was obtained from all subjects.

Anthropometric and biochemical measurements {#Sec10}
-------------------------------------------

After 10--12 hours fasting overnight, all participants were scheduled at the same time (0800--0900 h) and received the comprehensive physical examination. Height, body weight, WC, hip circumstance and BP were measured by the same observer, and the waist-to-hip ratio (WHR) and Body mass index (BMI, weight divided by height squared) were calculated. The percentage of body fat (FAT %) was measured by bioelectrical impedance (BIA-101; RJL Systems, Shenzhen, China). The homeostasis model assessment of IR (HOMA-IR) was calculated using the following equations: HOMA-IR = fasting insulin (mU/L) × FBG (mmol/L)/22.5^[@CR24]^. IR was defined as HOMA-IR value ≥ 3.8^[@CR25]^. A 75-g OGTT was performed between 0730 and 0830 h. Blood samples were drawn at 0, 30, 60, and 120 min for the demonstration of glucose, insulin, blood fat and BMP-9. Blood glucose and HbA1c were measured by the glucose-oxidase method and anion- exchange HPLC, respectively. Plasma insulin concentrations were measured in 317 individuals using chemiluminescence. Free fatty acids (FFAs) were measured with a commercial kit (Randox Laboratories Ltd., Antrim, UK). Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) were determined enzymatically using an autoanalyzer (Hitachi 747; Hitachi, Tokyo, Japan).

Measurements of circulating BMP-9 levels {#Sec11}
----------------------------------------

Plasma BMP-9 concentrations were measured in duplicate with an ELISA kit according to the manufacturer's protocol (R&D Systems, Inc., Catalog number DY3209, MN, USA). Briefly, 100 µl plasma was applied to the test BMP-9 concentrations. Then, 100 µl of specific biotin-conjugated anti-human BMP-9 was added to each well and incubated at 25 °C for 2 h. Each well was then washed three times. Colorimetric reaction was performed for 20 min with the use of horseradish peroxidase--conjugated streptavidin as substrate. A calibration curve was constructed by plotting the absorbance values at 450 nm versus the BMP-9 concentrations of the calibrators, and concentrations of samples were determined using this calibration curve. The minimum detectable concentration of human BMP-9 is \<15.6 µg/L. The intra- and inter-assay coefficients of variation (CV) were low than 5% and 10%, respectively. The linear range of the assay was 15.60--1,000 µg/L. As in previous study^[@CR10]^, we did not find that serum lipids or protein have effect on BMP-9 detection.

Statistical analysis {#Sec12}
--------------------

Data are expressed as means ± standard deviation (SD) or medium (25th and 75th percentiles). Kolmogorov-Smirnov test was applied to test the normality of distribution. Data that were not normally distributed were log transformed. The differences of the anthropometric measurements and other parameters between groups were tested by independent student *t*-test or ANOVA. spearman correlation coefficients, partial correlation coefficients and multiple linear regressions were calculated to analysis the relationship between BMP9 and other parameters. Binary logistic regression model was applied to control the possible confounding variables and assess the relationship between BMP9 levels and MetS. Odds ratio (OR) and 95% confidence interval (CI) were also calculated. Logistic regression analysis was also used to assess and compare the odds of developing MetS of different BMP-9 tertile categories. The trends of BMP-9 levels associated with MetS were analyzed using the Cochran-Armitage trend test and the row mean score difference. Receiver operating characteristics (ROC) curves of BMP-9 levels were constructed to determine the optimal cutoff point for the prediction of MetS and IR. *P* value \< 0.05 considered statistically significant.
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